{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T22:54:40Z","timestamp":1784415280914,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12886-018-0719-0","type":"journal-article","created":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T03:36:29Z","timestamp":1519097789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients"],"prefix":"10.1186","volume":"18","author":[{"given":"Ji Hwan","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Seungkyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Chul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,20]]},"reference":[{"issue":"17","key":"719_CR1","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","volume":"341","author":"T Sakane","year":"1999","unstructured":"Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Engl J Med. 1999;341(17):1284\u201391.","journal-title":"N Engl J Med"},{"issue":"1","key":"719_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3109\/08830189709116845","volume":"14","author":"RB Nussenblatt","year":"1997","unstructured":"Nussenblatt RB. Uveitis in Behcet's disease. Int Rev Immunol. 1997;14(1):67\u201379.","journal-title":"Int Rev Immunol"},{"issue":"8647","key":"719_CR3","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","volume":"1","author":"K Masuda","year":"1989","unstructured":"Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet Lon Engl. 1989;1(8647):1093\u20136.","journal-title":"Lancet Lon Engl"},{"issue":"5","key":"719_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1056\/NEJM199002013220501","volume":"322","author":"H Yazici","year":"1990","unstructured":"Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, Serdaroglu S, Oguz V, Yurdakul S, Lovatt GE, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med. 1990;322(5):281\u20135.","journal-title":"N Engl J Med"},{"issue":"4","key":"719_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1076\/ocii.8.4.293.6453","volume":"8","author":"B Wechsler","year":"2000","unstructured":"Wechsler B, Bodaghi B, Huong DL, Fardeau C, Amoura Z, Cassoux N, Piette JC, LeHoang P. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet's disease. Ocul Immunol Inflamm. 2000;8(4):293\u2013301.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"719_CR6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/bjo.87.4.423","volume":"87","author":"I Kotter","year":"2003","unstructured":"Kotter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Gunaydin I, Grimbacher B, Blaschke S, Meyer-Riemann W, Peter HH, et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87(4):423\u201331.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"719_CR7","first-page":"896","volume":"35","author":"L Krause","year":"2008","unstructured":"Krause L, Altenburg A, Pleyer U, Kohler AK, Zouboulis CC, Foerster MH. Longterm visual prognosis of patients with ocular Adamantiades-Behcet's disease treated with interferon-alpha-2a. J Rheumatol. 2008;35(5):896\u2013903.","journal-title":"J Rheumatol"},{"issue":"9","key":"719_CR8","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1002\/art.27581","volume":"62","author":"CM Deuter","year":"2010","unstructured":"Deuter CM, Zierhut M, Mohle A, Vonthein R, Stobiger N, Kotter I. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet's disease. Arthritis Rheum. 2010;62(9):2796\u2013805.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"719_CR9","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.ophtha.2009.11.022","volume":"117","author":"G Sobaci","year":"2010","unstructured":"Sobaci G, Erdem U, Durukan AH, Erdurman C, Bayer A, Koksal S, Karagul S, Bayraktar MZ. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet's uveitis refractory to conventional treatments. Ophthalmology. 2010;117(7):1430\u20135.","journal-title":"Ophthalmology"},{"issue":"3","key":"719_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/archophthalmol.2011.3","volume":"129","author":"S Onal","year":"2011","unstructured":"Onal S, Kazokoglu H, Koc A, Akman M, Bavbek T, Direskeneli H, Yavuz S. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis. Arch Ophthalmol. 2011;129(3):288\u201394.","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"719_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1089\/jop.2011.0238","volume":"28","author":"FN Yalcindag","year":"2012","unstructured":"Yalcindag FN, Uzun A. Results of interferon alpha-2a therapy in patients with Behcet's disease. J Ocul Pharmacol Ther. 2012;28(4):439\u201343.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"719_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/09273948.2016.1206204","volume":"25","author":"E Diwo","year":"2017","unstructured":"Diwo E, Gueudry J, Saadoun D, Weschler B, LeHoang P, Bodaghi B. Long-term efficacy of interferon in severe uveitis associated with Behcet disease. Ocul Immunol Inflamm. 2017;25(1):76\u201384.","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"719_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3109\/09273948.2015.1133835","volume":"25","author":"M Hasanreisoglu","year":"2017","unstructured":"Hasanreisoglu M, Cubuk MO, Ozdek S, Gurelik G, Aktas Z, Hasanreisoglu B. Interferon alpha-2a therapy in patients with refractory Beh\u00e7et uveitis. Ocul Immunol Inflamm. 2017;25(1):71\u20135.","journal-title":"Ocul Immunol Inflamm"},{"key":"719_CR14","unstructured":"International Study Group for Becet's Disease. Critertia for diagnosis of Behcet's disease. Lancet (London, England). 1990;335(8697):1078\u201380."},{"issue":"3","key":"719_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509\u201316.","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"719_CR16","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1093\/rheumatology\/keu266","volume":"53","author":"V Calvo-Rio","year":"2014","unstructured":"Calvo-Rio V, Blanco R, Beltran E, Sanchez-Burson J, Mesquida M, Adan A, Hernandez MV, Hernandez Garfella M, Valls Pascual E, Martinez-Costa L, et al. Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford). 2014;53(12):2223\u201331.","journal-title":"Rheumatology (Oxford)"},{"issue":"4 Suppl 84","key":"719_CR17","first-page":"S75","volume":"32","author":"M Papo","year":"2014","unstructured":"Papo M, Bielefeld P, Vallet H, Seve P, Wechsler B, Cacoub P, Le Hoang P, Papo T, Bodaghi B, Saadoun D. Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S75\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"719_CR18","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.ajo.2008.08.038","volume":"146","author":"J Gueudry","year":"2008","unstructured":"Gueudry J, Wechsler B, Terrada C, Gendron G, Cassoux N, Fardeau C, Lehoang P, Piette JC, Bodaghi B. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease. Am J Ophthalmol. 2008;146(6):837\u201344. e831","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"719_CR19","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3349\/ymj.2015.56.4.1158","volume":"56","author":"JY Park","year":"2015","unstructured":"Park JY, Chung YR, Lee K, Song JH, Lee ES. Clinical experience of interferon alfa-2a treatment for refractory uveitis in Behcet's disease. Yonsei Med J. 2015;56(4):1158\u201362.","journal-title":"Yonsei Med J"},{"issue":"12","key":"719_CR20","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","volume":"244","author":"I Tugal-Tutkun","year":"2006","unstructured":"Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol. 2006;244(12):1692\u20135.","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-018-0719-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:25:42Z","timestamp":1550622342000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-018-0719-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,20]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["719"],"URL":"https:\/\/doi.org\/10.1186\/s12886-018-0719-0","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,20]]},"assertion":[{"value":"16 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of Severance hospital (IRB No.4\u20132017-0436) and was conducted in accordance with the Declaration of Helsinki. Consent to participate from the patients was waived by the Institutional Review Board of Severance hospital (IRB No.4\u20132017-0436) as this was a retrospective chart review study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"52"}}